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 Animal models provide powerful tools for dissecting dose-response relationships and 
pathogenic mechanisms and for testing new treatment paradigms.  Mechanistic research on 
beryllium exposure-disease relationships is severely limited by a general inability to develop a 
sufficient chronic beryllium disease animal model.  Discovery of the Human Leukocyte 
Antigen (HLA) - DPB1Glu69 genetic susceptibility component of chronic beryllium disease 
permitted the addition of this human beryllium antigen presentation molecule to an animal 
genome which may permit development of a better animal model for chronic beryllium 
disease.  Using FVB/N inbred mice, Drs. Rubin and Zhu, successfully produced three strains 
of HLA-DPB1 Glu 69 transgenic mice.  Each mouse strain contains a haplotype of the HLA-
DPB1 Glu 69 gene that confers a different magnitude of odds ratio (OR) of risk for chronic 
beryllium disease: HLA-DPB1*0401 (OR = 0.2), HLA-DPB1*0201 (OR = 15), HLA-DPB1*1701 
(OR = 240).  In addition, Drs. Rubin and Zhu developed transgenic mice with the human CD4 
gene to permit better transmission of signals between T cells and antigen presenting cells.  This 




 The purpose of this project is to provide the scientific community with an animal model 
which will allow the study of chronic beryllium disease.  To achieve this goal we are 
maintaining the existing HLA-DPB1 Glu 69 and CD4 transgenic mice colonies.  Also, to insure 
that the human transgenes are functional in the 3 transgenic strains with the HLA-DPB1 Glu 
69 gene, we have challenged these mice with beryllium using dermal exposure. 




1. With one exception, the transgenic mice have been maintained successfully.  The exception, 
unfortunately, has been the instability of the HLA-DPB1*1701 transgene the mice.  After the 
successful completion of the first ear swelling functional assay (manuscript submitted), we 
determined by routine genotyping of the mice bred over the next 6 months that the HLA-
DPB1*1701 gene was unstable.  Dr. Zhu shipped us the DNA for the HLA-DPB1*1701 
transgene and we have generated new HLA-DPB1*1701 mice in the NYU School of Medicine’s 
Transgenic Mouse Core Facility. 
 
2. To monitor the functional expression of the human transgenes in the mice, the immunologic 
sensitivity of the 3 HLA-DPB1 Glu 69 transgenic strains has been evaluated with an ear 
swelling bio-assay which involves skin sensitization and an ear challenge with beryllium 
sulfate. As reported last year, the HLA-DPB1*1701 transgenic mice, the strain with the highest 
risk transgene in human workers, had significantly increased ear swelling when sensitized 
dermally with beryllium and challenged on the ear with beryllium.  No significant changes 
were observed in the other (HLA-DPB1*0201 and HLA-DPB1*0401) transgenic strains or the 
FVB/N background strain for any treatment condition.  These results suggested that the HLA-
DPB1*1701 transgene product was responsible for inducing a beryllium-sensitive phenotype 
and that this transgenic mouse model will be a useful tool for investigating beryllium 
sensitization and lung lesions. 
 
3. We successfully repeated this transgenic mouse ear swelling study for confirmatory reasons.    
In parallel studies (funded by NIEHS), we next tested 7 inbred strains of mice in a similar 
fashion and observed significant interstrain differences in the ear swelling test, thus suggesting 
that a genetic host factor controls the sensitization response in our mouse model.  To identify 
candidate genes that might be responsible for the genetic component of skin sensitization to 
beryllium, 21 different inbred mouse strains were utilized to see if they would exhibit varying 
hypersensitivity responses to beryllium in the mouse ear swelling test.  The SJL/J strain 
appeared to exhibit the greatest hypersensitivity responses with a 38% increase over the 
baseline ear thickness in the Be sensitized/Be challenged group compared with a 3% increase 
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in the control vehicle group. The FVB/N strain, in contrast, did not have significant increases 
in ear thickness.  The data for the 21 strains have been analyzed by haplotype mapping to 
uncover genes associated with sensitization to beryllium.  In collaboration with Drs. Delano 
and Wiltshire (Novartis), a significant locus was identified on chromosome 3 by haplotype 
analysis.  Vav3, a protein which is thought to orchestrate signaling events downstream of 
lymphocyte antigen receptors and is involved in lymphocyte development and activation 
(processes which would be highly important during beryllium sensitization), is a promising 
candidate gene located within the identified locus. 
 
3. In an in vivo study (funded by NIEHS), seven inbred strains of mice were aspirated with 20 
to 50 µg of beryllium metal particle or water vehicle monthly.  As in the ear swelling test, clear 
strain differences in beryllium-induced lymphogranulomatus nodules were observed.  The 
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